{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:31:14Z","timestamp":1790487074705,"version":"4.1.0"},"reference-count":148,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of patients with chronic myeloid leukemia (CML). However, continued use of these inhibitors has contributed to the increase in clinical resistance and the persistence of resistant leukemic stem cells (LSCs). So, there is an urgent need to introduce additional targeted and selective therapies to eradicate quiescent LSCs, and to avoid the relapse and disease progression. Here, we focused on emerging BCR-ABL targeted and non-BCR-ABL targeted drugs employed in clinical trials and on alternative CML treatments, including antioxidants, oncolytic virus, engineered exosomes, and natural products obtained from marine organisms that could pave the way for new therapeutic approaches for CML patients.<\/jats:p>","DOI":"10.3389\/fonc.2021.801779","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T08:38:41Z","timestamp":1639557521000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Emanuela","family":"Andretta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consiglia","family":"Longobardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pagnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Montagnaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Quintiliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Lauritano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ciarcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic Myeloid Leukemia: 2020 Update on Diagnosis, Therapy and Monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of Chronic Myeloid Leukaemia: An Update","volume":"94","author":"H\u00f6glund","year":"2015","journal-title":"Ann Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI41246","article-title":"Chronic Myeloid Leukemia: Mechanisms of Blastic Transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01132","article-title":"Management of Chronic Myeloid Leukemia in Advanced Phase","volume":"9","author":"Bonifacio","year":"2019","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00939","article-title":"BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia","volume":"9","author":"Loscocco","year":"2019","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.546912","article-title":"Chronic Myeloid Leukemia Cells Refractory\/Resistant to Tyrosine Kinase Inhibitors Are Genetically Unstable and may Cause Relapse and Malignant Progression to the Terminal Disease State","volume":"52","author":"Skorski","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.17-0175","article-title":"Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment","volume":"7","author":"Arrigoni","year":"2018","journal-title":"Stem Cells Transl Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-Line Imatinib vs Second- And Third-Generation TKIs for Chronic-Phase CML: A Systematic Review and Meta-Analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00143","article-title":"Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic Malignancies","volume":"17","author":"Wilkes","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720966120","article-title":"Tyrosine Kinase Inhibitors and Pregnancy in Chronic Myeloid Leukemia: Opinion, Evidence, and Recommendations","volume":"11","author":"Abruzzese","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.242891","article-title":"Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: When and for Whom","volume":"105","author":"Atallah","year":"2020","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001772","article-title":"Late Molecular Recurrences in Patients With Chronic Myeloid Leukemia Experiencing Treatment-Free Remission","volume":"4","author":"Rousselot","year":"2020","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.12703\/r\/10-35","article-title":"Recent Advances in Understanding Chronic Myeloid Leukemia: Where do We Stand","volume":"10","author":"Kumar","year":"2021","journal-title":"Fac Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38672-x","article-title":"Novel Mutations in the Kinase Domain of BCR-ABL Gene Causing Imatinib Resistance in Chronic Myeloid Leukemia Patients","volume":"9","author":"Chandrasekhar","year":"2019","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.162140299","article-title":"Clinical Resistance to the Kinase Inhibitor STI-571 in Chronic Myeloid Leukemia by Mutation of Tyr-253 in the Abl Kinase Domain P-Loop","volume":"99","author":"Roumiantsev","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40259-013-0056-z","article-title":"Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)","volume":"28","author":"Abruzzese","year":"2014","journal-title":"BioDrugs"},{"key":"B18","volume-title":"Tasigna","year":"2007"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0308","article-title":"Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome\u2013Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib","volume":"14","author":"Hazarika","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B20","volume-title":"Sprycel","year":"2006"},{"key":"B21","volume-title":"Drug Approval Package","year":"2006"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL Kinase Domain Mutations Confer Polyclonal Resistance to the Tyrosine Kinase Inhibitor Imatinib (STI571) in Chronic Phase and Blast Crisis Chronic Myeloid Leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL Mutations in Patients With CML Treated With Imatinib Is Virtually Always Accompanied by Clinical Resistance, and Mutations in the ATP Phosphate-Binding Loop (P-Loop) Are Associated With a Poor Prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib Therapy in Chronic Myelogenous Leukemia: Strategies to Avoid and Overcome Resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-91439-8_1","article-title":"Imatinib Mesylate","volume":"212","author":"Waller","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"B26","volume-title":"EMA\/436309\/2013 EMEA\/H\/C\/000406 Glivec Imatinib","year":"2013"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0468","article-title":"Nilotinib in the Treatment of Chronic Myeloid Leukemia","volume":"15","author":"Sacha","year":"2019","journal-title":"Futur Oncol"},{"key":"B30","volume-title":"Center for Drug Evaluation and Research","year":"2007"},{"key":"B31","first-page":"27","article-title":"Dasatinib","volume-title":"Recent Results in Cancer Research","author":"Lindauer","year":""},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4161\/cc.10.2.14537","article-title":"Impact of BCR-ABL Mutations on Patients With Chronic Myeloid Leukemia","volume":"10","author":"Hochhaus","year":"2011","journal-title":"Cell Cycle"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting Optimal Second-Line Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia Patients After Imatinib Failure: Does the BCR-ABL Mutation Status Really Matter","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and Efficacy of Bosutinib (SKI-606) in Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0555","article-title":"The Role of Bosutinib in the Treatment of Chronic Myeloid Leukemia","volume":"16","author":"Gambacorti-Passerini","year":"2020","journal-title":"Futur Oncol"},{"key":"B36","volume-title":"Highlights of Prescribing Information. Bosulif (Bosutinib) Tablets, for Oral Use","year":"2012"},{"key":"B37","volume-title":"EMA\/178678\/2018 EMEA\/H\/C\/002373. Bosulif (Bosutinib) An Overview of Bosulif and Why It Is Authorised in the EU","year":"2018"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666171002142659","article-title":"Ponatinib: A Review of Efficacy and Safety","volume":"18","author":"Massaro","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"B39","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","article-title":"Ponatinib: A Review of Its Use in Adults With Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S189391","article-title":"Ponatinib: A Novel Multi-Tyrosine Kinase Inhibitor Against Human Malignancies","volume":"12","author":"Tan","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"B42","volume-title":"Highlights of Prescribing Information. Iclusig (Ponatinib) Tablets for Oral Use","year":"2016"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25118","article-title":"Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia","volume":"231","author":"Ciarcia","year":"2016","journal-title":"J Cell Physiol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clml.2016.09.012","article-title":"Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.994205","article-title":"Real-Life Comparison of Severe Vascular Events and Other Non-Hematological Complications in Patients With Chronic Myeloid Leukemia Undergoing Second-Line Nilotinib or Dasatinib Treatment","volume":"56","author":"Gora-Tybor","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1177\/2040620717719851","article-title":"Radotinib and Its Clinical Potential in Chronic-Phase Chronic Myeloid Leukemia Patients: An Update","volume":"8","author":"Eskazan","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.096776","article-title":"Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients With Resistance or Intolerance to BCR-ABL1 Tyrosine Kinase Inhibitors","volume":"99","author":"Kim","year":"2014","journal-title":"Haematologica"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0957","article-title":"Phase III Clinical Trial (RERISE Study) Results of Efficacy and Safety of Radotinib Compared With Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia","volume":"23","author":"Kwak","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib Efficacy and Safety in Philadelphia Chromosome-Positive Leukemia: Final 5-Year Results of the Phase 2 PACE Trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of Cardiovascular and Arteriothrombotic Adverse Events in Chronic-Phase CML Patients After Frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0623-7","article-title":"Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option","volume":"38","author":"Iurlo","year":"2018","journal-title":"Clin Drug Investig"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2517","article-title":"Upfront Low-Dose Ponatinib (15 Mg\/Day) for Multi-TKI Resistant Chronic Myeloid Leukemia","volume":"36","author":"Tefferi","year":"2018","journal-title":"Hematol Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106337","article-title":"Novel Therapeutic Approaches in Chronic Myeloid Leukemia","volume":"91","author":"\u00d6zg\u00fcr Yurtta\u015f","year":"2020","journal-title":"Leuk Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17474086.2021.1990034","article-title":"Novel BCR-ABL1 Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia","volume":"14","author":"Malik","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nature21702","article-title":"The Allosteric Inhibitor ABL001 Enables Dual Targeting of BCR\u2013Abl1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.138.138","article-title":"ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients With CML With Failure of Prior TKI Therapy","volume":"126","author":"Ottmann","year":"2015","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia After ABL Kinase Inhibitor Failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009984","article-title":"A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After \u22652 Prior TKIs","author":"Rea","year":"2021","journal-title":"Blood"},{"key":"B63","volume-title":"FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia","year":"2021"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124295","article-title":"An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, A Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients With TKI Resistant Chronic Myeloid Leukemia","volume":"134","author":"Jiang","year":"2019","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142142","article-title":"Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients With T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.exphem.2019.08.007","article-title":"BCR-ABL1 Tyrosine Kinase Inhibitor K0706 Exhibits Preclinical Activity in Philadelphia Chromosome-Positive Leukemia","volume":"77","author":"Antelope","year":"2019","journal-title":"Exp Hematol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129751","article-title":"Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients With Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing \u2265 3 Prior TKI Therapies: Initial Safety and Efficacy","volume":"134","author":"Cortes","year":"2019","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-Line Therapy for Chronic Myeloid Leukemia: Current Status and Future Directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2018-99-116803","article-title":"Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy","volume":"132","author":"Turkina","year":"2018","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127951","article-title":"PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I","volume":"134","author":"Turkina","year":"2019","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-8-565","article-title":"Development of Farnesyl Transferase Inhibitors: A Review","volume":"10","author":"Appels","year":"2005","journal-title":"Oncologist"},{"key":"B72","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11899-012-0150-1","article-title":"Signal Transduction in the Chronic Leukemias: Implications for Targeted Therapies","volume":"8","author":"Ahmed","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1973","article-title":"Efficacy of the Farnesyl Transferase Inhibitor R115777 in Chronic Myeloid Leukemia and Other Hematologic Malignancies","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23006","article-title":"Phase 1 Study of Tipifarnib in Combination With Imatinib for Patients With Chronic Myelogenous Leukemia in Chronic Phase After Imatinib Failure","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21590","article-title":"Pilot Study of Lonafarnib, a Farnesyl Transferase Inhibitor, in Patients With Chronic Myeloid Leukemia in the Chronic or Accelerated Phase That Is Resistant or Refractory to Imatinib Therapy","volume":"106","author":"Borthakur","year":"2006","journal-title":"Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22901","article-title":"Phase 1 Study of Lonafarnib (SCH 66336) and Imatinib Mesylate in Patients With Chronic Myeloid Leukemia Who Have Failed Prior Single-Agent Therapy With Imatinib","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/08977194.2012.660936","article-title":"Biology and Significance of the JAK\/STAT Signalling Pathways","volume":"30","author":"Kiu","year":"2012","journal-title":"Growth Factors"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-585943","article-title":"Targeting the JAK2-STAT5 Pathway in CML","volume":"124","author":"Valent","year":"2014","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.leukres.2018.10.002","article-title":"A Phase I Clinical Trial of Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia Patients With Molecular Evidence of Disease","volume":"74","author":"Sweet","year":"2018","journal-title":"Leuk Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination With Imatinib Mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.4254.4254","article-title":"A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) With Resistance to \u22652 BCR-ABL Tyrosine Kinase Inhibitors","volume":"112","author":"Zaritskey","year":"2008","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-018-0805-1","article-title":"Non ABL-Directed Inhibitors as Alternative Treatment Strategies for Chronic Myeloid Leukemia","volume":"17","author":"Massimino","year":"2018","journal-title":"Mol Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.60","article-title":"A Phase 2 Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","volume":"4","author":"Seymour","year":"2014","journal-title":"Blood Cancer J"},{"key":"B84","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3324\/haematol.2014.115279","article-title":"A Phase I Study of Danusertib (PHA-739358) in Adult Patients With Accelerated or Blastic Phase Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant or Intolerant to Imatinib and\/or Other Second Generation C-","volume":"100","author":"Borthakur","year":"2015","journal-title":"Haematologica"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30490","article-title":"Pioglitazone Together With Imatinib in Chronic Myeloid Leukemia: A Proof of Concept Study","volume":"123","author":"Rousselot","year":"2017","journal-title":"Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2217\/epi.11.73","article-title":"Epigenomics of Leukemia: From Mechanisms to Therapeutic Applications","volume":"3","author":"Florean","year":"2011","journal-title":"Epigenomics"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25939","article-title":"Phase I\/II Study of Dasatinib in Combination With Decitabine in Patients With Accelerated or Blast Phase Chronic Myeloid Leukemia","volume":"95","author":"Abaza","year":"2020","journal-title":"Am J Hematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11543","article-title":"Results of Decitabine (5-Aza-2?Deoxycytidine) Therapy in 130 Patients With Chronic Myelogenous Leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0612-8","article-title":"How We Use Venetoclax With Hypomethylating Agents for the Treatment of Newly Diagnosed Patients With Acute Myeloid Leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"key":"B90","doi-asserted-by":"publisher","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined Targeting of BCL-2 and BCR-ABL Tyrosine Kinase Eradicates Chronic Myeloid Leukemia Stem Cells","volume":"8","author":"Carter","year":"2016","journal-title":"Sci Transl Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1159\/000506346","article-title":"Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients With Philadelphia Chromosome-Positive Advanced Myeloid Leukemias","volume":"143","author":"Maiti","year":"2020","journal-title":"Acta Haematol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29240","article-title":"Final Analysis of the Efficacy and Safety of Omacetaxine Mepesuccinate in Patients With Chronic- or Accelerated-Phase Chronic Myeloid Leukemia: Results With 24 Months of Follow-Up","volume":"121","author":"Cortes","year":"2015","journal-title":"Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.4161\/cc.25116","article-title":"Adding a New Facet to STAT5 in CML: Multitasking for Leukemic Cells","volume":"12","author":"Warsch","year":"2013","journal-title":"Cell Cycle"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041177","article-title":"DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia","volume":"21","author":"Popp","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22140","article-title":"Dysregulated Calcium Homeostasis and Oxidative Stress in Chronic Myeloid Leukemia (CML) Cells","volume":"224","author":"Ciarcia","year":"2010","journal-title":"J Cell Physiol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S1658-3876(09)50039-8","article-title":"Studies on Biomarkers for Oxidative Stress in Patients With Chronic Myeloid Leukemia","volume":"2","author":"Singh","year":"2009","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s12291-008-0072-9","article-title":"Oxidative Stress and Antioxidant Status in Patients With Chronic Myeloid Leukemia","volume":"23","author":"Ahmad","year":"2008","journal-title":"Indian J Clin Biochem"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.123","article-title":"Anti-Oxidant Vitamin E Prevents Accumulation of Imatinib-Resistant BCR-ABL1 Kinase Mutations in CML-CP Xenografts in NSG Mice","volume":"27","author":"Nieborowska-Skorska","year":"2013","journal-title":"Leukemia"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1177\/1078155211416530","article-title":"Effect of Imatinib Therapy With and Without Turmeric Powder on Nitric Oxide Levels in Chronic Myeloid Leukemia","volume":"18","author":"Ghalaut","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8112","article-title":"Curcumin Differentially Affects Cell Cycle and Cell Death in Acute and Chronic Myeloid Leukemia Cells","volume":"15","author":"Mart\u00ednez-Castillo","year":"2018","journal-title":"Oncol Lett"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4204","article-title":"Curcumin Inhibits In Vitro and In Vivo Chronic Myelogenous Leukemia Cells Growth: A Possible Role for Exosomal Disposal of miR-21","volume":"6","author":"Taverna","year":"2015","journal-title":"Oncotarget"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3317","article-title":"Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells","volume":"21","author":"Wu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2013.180","article-title":"Curcumin Derivative C817 Inhibits Proliferation of Imatinib-Resistant Chronic Myeloid Leukemia Cells With Wild-Type or Mutant Bcr-Abl In Vitro","volume":"35","author":"Wu","year":"2014","journal-title":"Acta Pharmacol Sin"},{"key":"B104","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2015.07.008","article-title":"Reactive Oxygen Species in Redox Cancer Therapy","volume":"367","author":"Tong","year":"2015","journal-title":"Cancer Lett"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1042\/BST0351156","article-title":"Resveratrol as an Antioxidant and Pro-Oxidant Agent: Mechanisms and Clinical Implications","volume":"35","author":"de la Lastra","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20408","article-title":"Effect of Resveratrol on High Glucose-Induced Stress in Human Leukemia K562 Cells","volume":"94","author":"Chan","year":"2005","journal-title":"J Cell Biochem"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2014.132","article-title":"Resveratrol Induces Apoptosis of Human Chronic Myelogenous Leukemia Cells In Vitro Through P38 and JNK-Regulated H2AX Phosphorylation","volume":"36","author":"Wu","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.26686","article-title":"Effects of Antioxidants on Apoptosis Induced by Dasatinib and Nilotinib in K562 Cells","volume":"119","author":"Damiano","year":"2018","journal-title":"J Cell Biochem"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2016.676","article-title":"Oncology\u2019s Trojan Horse: Using Viruses to Battle Cancer","volume":"31","author":"Mavani","year":"2016","journal-title":"Consult Pharm"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1723363","article-title":"Recent Advances of Oncolytic Virus in Cancer Therapy","volume":"16","author":"Mondal","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113219","article-title":"Past, Present and Future of Oncolytic Reovirus","volume":"12","author":"M\u00fcller","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B112","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coviro.2016.06.009","article-title":"Recent Advances in Oncolytic Adenovirus Therapies for Cancer","volume":"21","author":"Rosewell Shaw","year":"2016","journal-title":"Curr Opin Virol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-014-0223-y","article-title":"Oncolytic Parvoviruses: From Basic Virology to Clinical Applications","volume":"12","author":"Marchini","year":"2015","journal-title":"Virol J"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700946","article-title":"Herpes Simplex Virus 1 (HSV-1) for Cancer Treatment","volume":"13","author":"Shen","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/89901","article-title":"Replication-Selective Virotherapy for Cancer: Biological Principles, Risk Management and Future Directions","volume":"7","author":"Kirn","year":"2001","journal-title":"Nat Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/15384047.2018.1504722","article-title":"Caprine Herpesvirus 1 (CpHV-1) as a Potential Candidate for Oncolytic Virotherapy","volume":"20","author":"Montagnaro","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e0195425","DOI":"10.1371\/journal.pone.0195425","article-title":"Oncolytic Effect of Wild-Type Newcastle Disease Virus Isolates in Cancer Cell Lines In Vitro and In Vivo on Xenograft Model","volume":"13","author":"Yurchenko","year":"2018","journal-title":"PLoS One"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2009.77","article-title":"Bovine Herpesvirus Type 1 as a Novel Oncolytic Virus","volume":"17","author":"Rodrigues","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2009.3","article-title":"Armed Replicating Adenoviruses for Cancer Virotherapy","volume":"16","author":"Cody","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28010019","article-title":"Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs","volume":"28","author":"Innao","year":"2020","journal-title":"Curr Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1018","article-title":"Potent Antitumor Activity of Oncolytic Adenovirus Expressing Beclin-1 via Induction of Autophagic Cell Death in Leukemia","volume":"4","author":"Tong","year":"2013","journal-title":"Oncotarget"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2017.100","article-title":"Combing Oncolytic Adenovirus Expressing Beclin-1 With Chemotherapy Agent Doxorubicin Synergistically Enhances Cytotoxicity in Human CML Cells In Vitro","volume":"39","author":"Li","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201211138","article-title":"Extracellular Vesicles: Exosomes, Microvesicles, and Friends","volume":"200","author":"Raposo","year":"2013","journal-title":"J Cell Biol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12679","article-title":"The Potential of Exosomes Derived From Chronic Myelogenous Leukaemia Cells as a Biomarker","volume":"38","author":"Kang","year":"2018","journal-title":"Anticancer Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2199-z","article-title":"Up-Regulated Exosomal miRNA-140-3p in CML Patients With Musculoskeletal Pain Associated With Discontinuation of Tyrosine Kinase Inhibitors","volume":"105","author":"Asano","year":"2017","journal-title":"Int J Hematol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.7150\/thno.17092","article-title":"Interleukin 3- Receptor Targeted Exosomes Inhibit In Vitro and In Vivo Chronic Myelogenous Leukemia Cell Growth","volume":"7","author":"Bellavia","year":"2017","journal-title":"Theranostics"},{"key":"B127","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1039\/c7np00052a","article-title":"Marine Natural Products","volume":"35","author":"Blunt","year":"2018","journal-title":"Nat Prod Rep"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1017\/S0025315415002106","article-title":"The Marine Biodiscovery Pipeline and Ocean Medicines of Tomorrow","volume":"96","author":"Jaspars","year":"2016","journal-title":"J Mar Biol Assoc United Kingdom"},{"key":"B129","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.marenvres.2016.05.002","article-title":"Marine Microorganisms as a Promising and Sustainable Source of Bioactive Molecules","volume":"128","author":"Romano","year":"2017","journal-title":"Mar Environ Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094383","article-title":"Unlocking the Health Potential of Microalgae as Sustainable Sources of Bioactive Compounds","volume":"22","author":"Saide","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/md19080459","article-title":"Bioactivity Screening of Antarctic Sponges Reveals Anticancer Activity and Potential Cell Death via Ferroptosis by Mycalols","volume":"19","author":"Riccio","year":"2021","journal-title":"Mar Drugs"},{"key":"B132","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1038\/s41598-020-61515-z","article-title":"First Evidence of Anticancer and Antimicrobial Activity in Mediterranean Mesopelagic Species","volume":"10","author":"Lauritano","year":"2020","journal-title":"Sci Rep"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/md16050165","article-title":"Marine Microalgae With Anti-Cancer Properties","volume":"16","author":"Mart\u00ednez Andrade","year":"2018","journal-title":"Mar Drugs"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1021\/np0581216","article-title":"Natural Product Extracts of Plant and Marine Origin Having Antileukemia Potential. The NCI Experience","volume":"69","author":"Cragg","year":"2006","journal-title":"J Nat Prod"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1021\/np4003367","article-title":"Gombamide A, a Cyclic Thiopeptide From the Sponge Clathria Gombawuiensis","volume":"76","author":"Woo","year":"2013","journal-title":"J Nat Prod"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1021\/np500156n","article-title":"Suvanine Sesterterpenes and Deacyl Irciniasulfonic Acids From a Tropical Coscinoderma Sp. Sponge","volume":"77","author":"Kim","year":"2014","journal-title":"J Nat Prod"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4020(02)00519-7","article-title":"Structure\u2013activity Relationship of Neuritogenic Spongean Acetylene Alcohols, Lembehynes","volume":"58","author":"Aoki","year":"2002","journal-title":"Tetrahedron"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1039\/C6OB02346K","article-title":"The First Total Synthesis of the Marine Acetylenic Alcohol, Lembehyne B \u2013 A Selective Inducer of Early Apoptosis in Leukemia Cancer Cells","volume":"15","author":"Dzhemileva","year":"2017","journal-title":"Org Biomol Chem"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3390\/md16060212","article-title":"Breaking Down Leukemia Walls: Heteronemin, a Sesterterpene Derivative, Induces Apoptosis in Leukemia Molt4 Cells Through Oxidative Stress, Mitochondrial Dysfunction and Induction of Talin Expression","volume":"16","author":"Chen","year":"2018","journal-title":"Mar Drugs"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3390\/md6030480","article-title":"Smenospongine, a Sesquiterpene Aminoquinone From a Marine Sponge, Induces G1 Arrest or Apoptosis in Different Leukemia Cells","volume":"6","author":"Kong","year":"2008","journal-title":"Mar Drugs"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3390\/ijms12117352","article-title":"Antiproliferative Effect of Aaptamine on Human Chronic Myeloid Leukemia K562 Cells","volume":"12","author":"Jin","year":"2011","journal-title":"Int J Mol Sci"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3390\/md12052760","article-title":"New Cyclic Cystine Bridged Peptides From the Sponge Suberites Waedoensis","volume":"12","author":"Song","year":"2014","journal-title":"Mar Drugs"},{"key":"B143","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-69075-9_11","article-title":"Grand Challenges in Marine Biotechnology: Overview of Recent EU-Funded Projects","volume-title":"Grand Challenges in Biology and Biotechnology","author":"Lauritano","year":"2018"},{"key":"B144","doi-asserted-by":"publisher","first-page":"e0196195","DOI":"10.1371\/journal.pone.0196195","article-title":"Zebrafish-Based Identification of the Antiseizure Nucleoside Inosine From the Marine Diatom Skeletonema Marinoi","volume":"13","author":"Brillatz","year":"2018","journal-title":"PLoS One"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3390\/md18050257","article-title":"Pheophorbide a: State of the Art","volume":"18","author":"Saide","year":"2020","journal-title":"Mar Drugs"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s11101-010-9200-2","article-title":"Photosynthetic Marine Organisms as a Source of Anticancer Compounds","volume":"9","author":"Folmer","year":"2010","journal-title":"Phytochem Rev"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.9.9.1207","article-title":"Marine Natural Products as Therapeutic Agents","volume":"9","author":"Kerr","year":"1999","journal-title":"Expert Opin Ther Pat"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2015.12.001","article-title":"Screening of New Antileukemic Agents From Essential Oils of Algae Extracts and Computational Modeling of Their Interactions With Intracellular Signaling Nodes","volume":"83","author":"Atasever-Arslan","year":"2016","journal-title":"Eur J Pharm Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.801779\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T06:33:13Z","timestamp":1640068393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.801779\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":148,"alternative-id":["10.3389\/fonc.2021.801779"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.801779","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"article-number":"801779"}}